Avastin bevacizumab: Additional Phase III data

Additional data from the double-blind, international Phase III AVAglio trial in 921 patients with newly diagnosed glioblastoma showed that Avastin plus temozolomide and radiation led to a median PFS, a co-primary endpoint, of 10.6 months vs. 6.2 months for placebo plus

Read the full 410 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE